Aethlon Medical: Final Cohort Enrolled, Biomarker Signals Strengthen, Cash Extended
Micro-cap Hemopurifier developer nears completion of oncology trial with positive EV removal data and plans to expand beyond cancer.
AEMD · Earnings Call · 2026-08-13
Clinical Milestone in the Australian Oncology Trial
Aethlon Medical has entered the final cohort of its Australian oncology trial, a dose-escalation study of the Hemopurifier in patients with solid tumors. The first participant in Cohort 3 received three 4-hour treatments over a week, and no device-related serious adverse events or dose-limiting toxicity have been observed. Management expects to complete all treatments and the 8-week follow-up by the end of 2026. “Our goal remains to complete all HP treatments and the 8-week follow-up central lab measurement period by the end of this year, 2026.” — Steven Larosa · 2026-08-13 This sets the stage for formal analysis and regulatory discussions. The preliminary data from Cohort 2, where participants received two treatments, continues to show encouraging biomarker changes. “We continue to see decreases in total extracellular vesicle counts, including tumor-derived extracellular vesicles and microRNAs linked to cancer progression following the HP treatment.” — Steven Larosa · 2026-08-13 Moreover, increases in lymphocyte subsets and favorable shifts in laboratory ratios associated with immunotherapy responses were more consistent and longer-lasting than in Cohort 1. As Chief Medical Officer Steven LaRosa noted, “it looks like the biologic signal is more consistent across 3 participants in Cohort 2... we're seeing more times in Cohort 2 where we're seeing the positive directional change go out as far as the 8-week time period.” — Steven Larosa · 2026-08-13 This directional change suggests a potential dose-response effect that Cohort 3 will test with a third treatment per week.Financial Discipline and a Strengthened Balance Sheet
The company ended the quarter with $4.9 million in cash and subsequently raised $4 million through a public offering. “we believe our cash resources are sufficient to fund operations for at least the next 12 months.” — James Frakes, Chief Executive Officer and Chief Financial Officer · 2026-08-13 Operating expenses fell 11.9% year-over-year, driven by lower professional fees and reduced R&D and G&A costs. The Hemopurifier platform continues to be advanced with a lean budget, leveraging in-house lab work and samples obtained at minimal cost. R&D spending has been cut sharply, yet clinical momentum has accelerated. The cash runway metric from the fundamentals shows only 2.9 quarters as of June 30, but the subsequent raise extends it. This is a micro-cap with a market cap of just over $3 million, so financing risk remains central.Expanding the Platform Beyond Oncology
Aethlon is also building evidence for the Hemopurifier in other disease areas where extracellular vesicles play a role. The Long COVID study was published in the International Journal of Molecular Sciences in June 2026, demonstrating that the GNA resin binds EVs from Long COVID patients and reduces microRNAs linked to immune dysregulation. The company is planning discussions with academic and regulatory bodies to chart a development path. Additionally, preclinical work is exploring applications in lupus, heart disease with chronic kidney disease. This aligns with the long-standing Hemopurifier platform strategy of broadening the addressable market without heavy near-term spend.Market Reaction and Outlook
The stock has been extremely volatile, with a 460% spike in the nine days following the earnings release, before pulling back 11%. The recent 90-day trend shows a +25.8% gain. The market is clearly telegraphing hope that the final cohort data will confirm a dose-response and open the door to a pivotal trial. However, the company remains a speculative investment; the success of the trial is far from guaranteed, and additional capital will likely be needed. As Jim Frakes emphasized in closing,That discipline will be tested as the data readout approaches. R&D expenses fell 56% year-over-year, reflecting the company's focus on cost containment while still executing on the final cohort.We remain focused on advancing the Hemopurifier platform through disciplined clinical execution, rigorous analysis of our data and careful capital management.